DexCom, Inc. (DXCM)
- Previous Close
130.10 - Open
130.18 - Bid 129.53 x 100
- Ask 129.80 x 100
- Day's Range
129.17 - 130.23 - 52 Week Range
74.75 - 142.00 - Volume
166,368 - Avg. Volume
3,166,283 - Market Cap (intraday)
51.532B - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
84.69 - EPS (TTM)
1.53 - Earnings Date Jul 25, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
153.37
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
www.dexcom.comRecent News: DXCM
Performance Overview: DXCM
Trailing total returns as of 5/8/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DXCM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DXCM
Valuation Measures
Market Cap
51.71B
Enterprise Value
51.41B
Trailing P/E
84.44
Forward P/E
71.43
PEG Ratio (5yr expected)
2.34
Price/Sales (ttm)
14.54
Price/Book (mrq)
23.02
Enterprise Value/Revenue
13.52
Enterprise Value/EBITDA
51.64
Financial Highlights
Profitability and Income Statement
Profit Margin
16.82%
Return on Assets (ttm)
6.79%
Return on Equity (ttm)
28.54%
Revenue (ttm)
3.8B
Net Income Avi to Common (ttm)
639.3M
Diluted EPS (ttm)
1.53
Balance Sheet and Cash Flow
Total Cash (mrq)
2.9B
Total Debt/Equity (mrq)
115.28%
Levered Free Cash Flow (ttm)
524.36M
Research Analysis: DXCM
Company Insights: DXCM
DXCM does not have Company Insights